Loading the security overview…
Where the tokens are
Peers
10 of 14 have tokenized versionsFirst the companies classified under the same themes, most themes in common first; then the ones investors most often look at alongside ASND. A peer with a tokenized version links to its own page, where every issuer that wraps it is listed.
| Company | Shared themes | Market cap | P/E | P/S | EV/EBITDA | ROE | F-Score | Altman zone |
|---|---|---|---|---|---|---|---|---|
 ASNDThis companyAscendis Pharma A/S Ordinary Share | — | $17.53B | — | — | — | — | 2/9 | — |
 TMOTokenizedThermo Fisher Scientific, Inc. | Clinical-Stage Platforms | $241.26B | 34.6 | 5.2 | 24.6 | 13.2% | 6/9 | safe |
 ATokenizedAgilent Technologies Inc. | Clinical-Stage Platforms | $46.99B | 32.6 | 6.4 | 25.8 | 19.6% | 6/9 | safe |
 IQVTokenizedIQVIA Holdings Inc. | Clinical-Stage Platforms | $42.91B | 31.2 | 2.5 | 16.1 | 22.3% | 5/9 | grey |
 WATTokenizedWaters Corp | Clinical-Stage Platforms | $41.81B | 251.6 | 9.0 | 83.5 | 1.1% | 5/9 | safe |
 WSTTokenizedWest Pharmaceutical Services, Inc. | Clinical-Stage Platforms | $25.69B | 45.5 | 7.7 | 28.2 | 18.9% | 7/9 | safe |
 RPRXRoyalty Pharma plc Class A Ordinary Shares | Clinical-Stage Platforms | $25.66B | 31.5 | 10.1 | 19.8 | 11.9% | 6/9 | safe |
 MEDPTokenizedMedpace Holdings, Inc. Common Stock | Clinical-Stage Platforms | $16.69B | 34.0 | 6.0 | 26.5 | 113.3% | 6/9 | safe |
 RVTYTokenizedRevvity, Inc. | Clinical-Stage Platforms | $16.63B | 70.0 | 5.7 | 24.4 | 3.3% | 7/9 | safe |
 CRLCharles River Laboratories International, Inc. | Clinical-Stage Platforms | $13.69B | — | 3.4 | 21.1 | −8.4% | 6/9 | safe |
 ICLRIcon Plc | Clinical-Stage Platforms | $12.49B | 37.0 | 4.3 | 25.3 | 17.5% | 7/9 | grey |
 TWSTTokenizedTwist Bioscience Corporation Common Stock | Clinical-Stage Platforms | $12.47B | — | 28.9 | -110.0 | −30.7% | 3/9 | safe |
 HALOTokenizedHalozyme Therapeutics, Inc. | Clinical-Stage Platforms | $12.14B | 29.4 | 7.3 | 13.5 | 288.1% | 6/9 | safe |
 TECHBio-Techne Corp. | Clinical-Stage Platforms | $11.35B | 62.4 | 9.3 | 32.3 | 8.6% | 8/9 | safe |
 AVTRTokenizedAvantor, Inc. | Clinical-Stage Platforms | $10.17B | — | 1.6 | 15.0 | −10.3% | 4/9 | grey |
Figures describe Ascendis Pharma A/S shares, not any token. From theme classifications, Massive's related companies and the latest ratios and scores. Ratios are trailing, each as of its own latest filing. Peers are for comparison, not a list of alternatives to buy.